Concepedia

Gregg Timony

GT

Statistics

Publications

14

Citations

1.1K

H-Index

13

Active since

1990

Affiliations

Forma Therapeutics (United States)(Current)

Scripps Research Institute

Bristol-Myers Squibb (Switzerland)

Biogen (United States)

Gregg Timony is an author at Forma Therapeutics (United States) specializing in medicine, pharmacology, and medicinal chemistry.

Top concepts

Publications per year

1990–2024

14

Publications

14

Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P <sub>1</sub> ) and receptor‐5 (S1P <sub>5</sub> ) agonist with autoimmune disease‐modifying activity

Fiona L. Scott, Bryan Clemons, Jennifer L. Brooks et al. · British Journal of Pharmacology · 2016 · 296 citations · Full text

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Srinivas Rao Kasibhatla, Kevin Hong, Marco A. Biamonte et al. · Journal of Medicinal Chemistry · 2007 · 125 citations · Full text

, , +17

7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors

Lin Zhang, Junhua Fan, K. NGUYEN VU et al. · Journal of Medicinal Chemistry · 2006 · 114 citations · Full text

, , +18

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach et al. · The Journal of Clinical Pharmacology · 2017 · 106 citations · Full text

Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90

Jean‐Yves Le Brazidec, Adeela Kamal, David J. Busch et al. · Journal of Medicinal Chemistry · 2004 · 84 citations · Full text

, , +17

Rows per page

1–5 of 14